Vicore Pharma Holding
Vicore Pharma: Blockbuster Orphan Potential (Redeye)
2020-06-25 07:25
Redeye initiates coverage of Vicore Pharma, a clinical stage biotech name, focusing primarily on rare fibrotic disorders. An investment in Vicore offers highly attractive risk/reward at current levels, in our view. Its lead candidate is pursuing three phase II trials, including an interesting long shot at Covid-19. The compelling case also benefits from a distinguishing ability to bring drugs to market without partners, a solid cash position and strong owners.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se